:T

Yuan-Yuan Wang1,2, Wei-Lin Jin1

  • 1Institute of Cancer Neuroscience, Medical Frontier Innovation Research Center, The First Hospital of Lanzhou University, The First Clinical Medical College of Lanzhou University, 730000 Lanzhou, Gansu, China.

概括

质母细胞瘤 (GBM) 利用瘤衍生的IL-11触发T细胞死亡并将星体细胞重新编程为免疫抑制作用者. 一种针对瘤亡因子相关的亡诱导配体 (TRAIL) 的新型简单性疹病毒1型 (HSV-1) 疗法提供了针对GBM逃避的双重治疗策略.